Avantor vs Bio-Rad Laboratories
AVTR and BIO side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVTR and BIO compare
Avantor and Bio-Rad Laboratories are about the same size, with market caps of $10.9B and $10.0B.
Bio-Rad Laboratories grew revenue faster over the last twelve months (1.4% versus −1.6% for Avantor).
Bio-Rad Laboratories keeps more of each dollar of sales as profit, with a net margin of 8.6% compared with −8.8% at Avantor.
Bio-Rad Laboratories scores higher on the StockData Score (8 against 4 for Avantor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVTR | BIO |
|---|---|---|
| Size and price | ||
| Market cap | $10.9B | $10.0B |
| Share price | $16.05 | $372.18 |
| Change, 1 year | 38.6% | 16.5% |
| Change, 5 years | −58.0% | −48.7% |
| Beta (5Y) | 0.85 | 1.04 |
| Employees | 14K | 7,450 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 45.1× |
| P/S | 1.7× (better) | 3.8× |
| P/B | 1.9× | 1.4× (better) |
| EV/EBITDA | 121× (better) | 172× |
| P/FCF | 23.9× (better) | 28.2× |
| FCF yield | 4.2% (better) | 3.5% |
| Fair value | $19.89 | $239.52 |
| Margin of safety | 19.3% (better) | −55.4% |
| Growth | ||
| Revenue growth (TTM) | −1.6% | 1.4% (better) |
| Revenue growth, 5Y average | 0.49% (better) | 0.29% |
| Net income growth (TTM) | −184% | −30.3% (better) |
| EPS growth (TTM) | −185% | −29.7% (better) |
| EPS growth, 5Y average | – | −26.1% |
| Profitability | ||
| Gross margin | 31.8% | 51.9% (better) |
| Operating margin | −4.6% | 2.1% (better) |
| Net margin | −8.8% | 8.6% (better) |
| FCF margin | 6.9% | 13.6% (better) |
| Return on equity | −9.7% | 3.1% (better) |
| Return on invested capital | −2.5% | 0.51% (better) |
| Financial health | ||
| Debt / equity | 0.66 | 0.11 (better) |
| Net debt / EBITDA | 28.91 (better) | −15.36 |
| Interest coverage | −1.8× | 1.1× (better) |
| Current ratio | 1.78 | 3.14 (better) |
| Altman Z-score | 1.90 | 3.55 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 1.3% |
| Shareholder yield | 0.00% | 1.3% (better) |
| Ownership | ||
| Held by institutions | 103% | 83.2% |
| Held by insiders | 1.0% | 54.5% |
| Insider net buying, 12 months | $7.6M (better) | −$350K |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 5.9% | – |
Go deeper
- AVTR stock overview
- AVTR income statement
- AVTR valuation and score
- BIO stock overview
- BIO income statement
- BIO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.